for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biohaven Pharmaceutical Holding Co Ltd

BHVN.N

Latest Trade

53.93USD

Change

-0.92(-1.68%)

Volume

46,779

Today's Range

53.88

 - 

55.35

52 Week Range

29.17

 - 

67.86

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
54.85
Open
55.10
Volume
46,779
3M AVG Volume
13.97
Today's High
55.35
Today's Low
53.88
52 Week High
67.86
52 Week Low
29.17
Shares Out (MIL)
52.24
Market Cap (MIL)
2,865.37
Forward P/E
-5.58
Dividend (Yield %)
--

Latest Developments

More

Biohaven's Troriluzole Advances Past Interim Futility Analysis In Phase 2/3 Alzheimer's Disease Study

Biohaven Posts Q3 Loss Of $2.04/Shr

Biohaven Pharmaceutical Gives Rimegepant FDA Mid Cycle Communication Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biohaven Pharmaceutical Holding Co Ltd

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.

Industry

Biotechnology & Drugs

Contact Info

215 Church St

+1.203.4040410

http://biohavenpharma.com/

Executive Leadership

Thomas Lynch

Chairman of the Board

Vlad Coric

Chief Executive Officer, Director

James Engelhart

Chief Financial Officer, Treasurer

Kimberly A Gentile

Senior Vice President - Clinical Operations

Charles Conway

Chief Scientific Officer

Key Stats

1.60 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-5.000

2018

-6.150

2019(E)

-9.836
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
15.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
50.81
LT Debt To Equity (MRQ)
50.81
Return on Investment (TTM)
-115.81
Return on Equity (TTM)
-106.70

Latest News

Latest News

Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%.

Biohaven Pharma to continue late-stage study of Alzheimer's treatment

Biohaven Pharmaceutical said on Friday it would continue with a late-stage study of its experimental Alzheimer's treatment on the recommendation of an independent data-monitoring committee based on an interim analysis of results.

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.

Biohaven plunges as investors pit migraine data against Allergan's drug

Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.

Biohaven tumbles as migraine drug efficacy fails to impress investors

Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.

BRIEF-Biohaven Pharmaceutical Q4 Loss Per Share $0.75

Biohaven Pharmaceutical Holding Company Ltd:

BRIEF-Biohaven Pharma qtrly loss per share $1.19

Biohaven Pharmaceutical Holding Company Ltd

BRIEF-Biohaven appoints Clifford Bechtold as COO

Biohaven Pharmaceutical Holding Company Ltd

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up